

Quality-Data Code Submission Error Report 3rd Quarter 2010 Physician Quality Reporting System

Report Date: 12/21/2010

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

Column Definitions:

- Total QDCs Reported - Number of QDC submissions for a measure whether or not the QDC submission was valid and appropriate for a measure.
- Total Valid QDCs Reported - Number of valid and appropriate QDC submissions for a measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator criteria.
- Patient Age Mismatch - Patient did not meet age requirements for the measure.
- Patient Gender Mismatch - Patient did not meet gender requirement for the measure.
- Incorrect HCPCS - Incorrect HCPCS code for the measure - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis - Incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis and HCPCS - Combination of incorrect HCPCS code and incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Only QDC on Claim - Patient claim missing a qualifying denominator code (all line items contained only QDCs).
- Only QDC and Incorrect Diagnosis - Combination of missing qualifying denominator code and qualifying diagnosis code on the claim.
- Resubmitted QDCs - Submissions invalid due to resubmission of claims simply for the purpose of adding QDCs.
- Unattributed/No NPI - Submissions where the rendering NPI was missing.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column: 583,887 QDC submissions were received for this measure, 509,242 of which were considered valid. Therefore, the Valid Submission Rate is 87.22%. There were a total of 533,263 QDCs reported on eligible cases. The rest of the columns explain reasons for invalid submissions for measure #47. We see that 25,236 (4.32%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 45,940 (7.87%) submissions were for patient encounters that are not listed in the denominator; this measure applies to all Medicare Part B beneficiaries regardless of diagnosis; 4,684 (0.80%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, NPI/TIN. There were no submissions with a combination of QDC-only and diagnosis mismatch and no QDC resubmissions for this measure. There were also no submissions which lacked an NPI in the rendering provider ID field on the claim.

Analysis Findings Include:

1. There were 45 measures with percentage of valid QDC submitted greater than 90%. The top 3 measures with the highest percentage of valid QDCs submitted were:
 - #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (97.73%)
 - #147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.70%)
 - #177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity (97.58%).
2. There were 8 measures with percentage of valid QDC submitted less than 10%. The top 3 measures with the lowest percentage of valid QDCs submitted were:
 - #94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility (0.00%)
 - #66 Appropriate Testing for Children (0.10%)
 - #65 Appropriate Treatment for Children (0.15%).
3. There were 6 measures with percentage of age mismatch higher than 50%. The top 3 measures with highest percentage of age mismatch were:
 - #94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility (100.0%)
 - #66 Appropriate Testing for Children (99.70%)
 - #65 Appropriate Treatment for Children (99.55%).
4. 6 measures that were restricted to female patient had gender mismatch. All of the percentages of gender mismatch were lower than 4%.
5. 3 measures having the percentage of HCPCS errors greater than 50% were:
 - #20 Timing of Antibiotic Prophylaxis - Ordering Physician (91.62%)
 - #45 Discontinuation of Prophylactic Antibiotics (69.50%)
 - #181 Elder Maltreatment Screen and Follow-Up Plan (52.63%).
6. 3 measures having the percentage of diagnosis errors greater than 50% were:
 - #40 Management Following Fracture (90.25%)
 - #122 Blood Pressure Management (71.76%)
 - #55 ECG Performed for Syncope (57.81%).
7. There were 9 measures with the percentage of both diagnosis and HCPCS error greater than 50%. The top 3 measure with the highest percentage of both diagnosis and HCPCS errors were:
 - #94 OME: Diagnostic Evaluation Assessment of Tympanic Membrane Mobility (100%)
 - #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (98.54%)
 - #66 Appropriate Testing for Children (98.41%).

Quality-Data Code Submission Error Report by Measure
 Report Includes Data from the January through September 2010 TAP File

Topic Measure	QDC Submission Attempts			Denominator Mismatch ^a														Resubmitted QDCs ^f		Unattributed (No NPI) ^g	
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^c		Patient Gender Mismatch ^d		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC					
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
Advance Care Plan																					
#47 Advance Care Plan	583,887	509,242	87.22%	533,263	25,236	4.32%	0	0.00%	45,940	7.87%	0	0.00%	0	0.00%	4,684	0.80%	0	0.00%	0	0.00%	
Anesthesia																					
#193 Perioperative Temperature Management	1,032,932	966,366	93.56%	991,646	0	0.00%	0	0.00%	37,501	3.63%	0	0.00%	0	0.00%	3,785	0.37%	0	0.00%	0	0.00%	
Arthritis-Osteoarthritis																					
#109 Patients with OA with an Assessment of Pain and Function	65,340	54,475	83.37%	54,481	0	0.00%	0	0.00%	2,289	3.50%	6,471	9.90%	1,794	2.75%	194	0.30%	203	0.31%	0	0.00%	
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	61,006	42,677	69.96%	42,687	1	0.00%	0	0.00%	2,249	3.69%	14,915	24.45%	879	1.44%	190	0.31%	439	0.72%	0	0.00%	
Arthritis-Rheumatoid																					
#108 DMARD Therapy in Rheumatoid Arthritis	27,344	26,074	95.36%	26,091	0	0.00%	0	0.00%	251	0.92%	936	3.42%	24	0.09%	29	0.11%	39	0.14%	12	0.04%	
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	7,949	7,145	89.89%	7,778	0	0.00%	0	0.00%	62	0.78%	86	1.08%	6	0.08%	7	0.09%	8	0.10%	11	0.14%	
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	8,356	8,154	97.58%	8,157	0	0.00%	0	0.00%	45	0.54%	139	1.66%	6	0.07%	7	0.08%	9	0.11%	0	0.00%	
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	9,779	9,454	96.68%	9,458	0	0.00%	0	0.00%	59	0.60%	248	2.54%	4	0.04%	8	0.08%	15	0.15%	0	0.00%	
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	6,161	6,021	97.73%	6,031	0	0.00%	0	0.00%	36	0.58%	86	1.40%	2	0.03%	6	0.10%	4	0.06%	0	0.00%	
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	6,378	6,156	96.52%	6,257	0	0.00%	0	0.00%	41	0.64%	70	1.10%	3	0.05%	7	0.11%	4	0.06%	0	0.00%	
Asthma																					
#53 Pharmacologic Therapy	3,866	596	15.42%	684	3,116	80.60%	0	0.00%	20	0.52%	37	0.96%	3,026	78.27%	4	0.10%	95	2.46%	0	0.00%	
#64 Asthma Assessment	2,760	364	13.19%	364	2,373	85.98%	0	0.00%	8	0.29%	15	0.54%	2,244	81.30%	0	0.00%	130	4.71%	0	0.00%	
Audiology																					
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	820	2	0.24%	2	0	0.00%	0	0.00%	1	0.12%	8	0.98%	808	98.54%	0	0.00%	5	0.61%	0	0.00%	
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	98	37	37.76%	38	0	0.00%	0	0.00%	5	5.10%	39	39.80%	16	16.33%	0	0.00%	1	1.02%	0	0.00%	
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	1,014	907	89.45%	916	0	0.00%	0	0.00%	31	3.06%	54	5.33%	13	1.28%	0	0.00%	2	0.20%	0	0.00%	
Breast Cancer																					
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	62,308	56,319	90.39%	60,228	0	0.00%	316	0.51%	542	0.87%	1,004	1.61%	389	0.62%	135	0.22%	28	0.04%	0	0.00%	
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	43,250	23,587	54.54%	23,590	0	0.00%	0	0.00%	839	1.94%	16,043	37.09%	2,376	5.49%	221	0.51%	639	1.48%	0	0.00%	
#112 Screening Mammography	135,249	89,707	66.33%	89,744	37,072	27.41%	2,109	1.56%	40,405	29.87%	0	0.00%	0	0.00%	5,100	3.77%	0	0.00%	0	0.00%	
Bronchitis																					
#116 Inappropriate Antibiotic Treatment for Adults	671	149	22.21%	149	479	71.39%	0	0.00%	3	0.45%	34	5.07%	479	71.39%	1	0.15%	6	0.89%	0	0.00%	
CAD																					
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	741,167	690,809	93.21%	690,809	1	0.00%	0	0.00%	11,626	1.57%	34,829	4.70%	1,821	0.25%	1,781	0.24%	1,064	0.14%	0	0.00%	
Cataracts																					
#139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	462,751	444,499	96.06%	444,545	1	0.00%	0	0.00%	16,627	3.59%	0	0.00%	0	0.00%	1,579	0.34%	0	0.00%	0	0.00%	
Catheter-Related Bloodstream Infections (CRBSI)																					
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	170,431	152,985	89.76%	152,985	0	0.00%	0	0.00%	16,588	9.73%	0	0.00%	0	0.00%	858	0.50%	0	0.00%	0	0.00%	
Chest Pain																					
#54 ECG Performed for Non-Traumatic Chest Pain	1,095,288	799,883	73.03%	799,892	14,175	1.29%	0	0.00%	27,286	2.49%	243,175	22.20%	21,665	1.98%	2,218	0.20%	2,965	0.27%	0	0.00%	
Chiropractic Care																					
#182 Functional Outcome Assessment in Chiropractic Care	61,273	58,369	95.26%	58,369	0	0.00%	0	0.00%	2,617	4.27%	0	0.00%	0	0.00%	287	0.47%	0	0.00%	0	0.00%	

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Note: Individuals participating in GPRO are excluded from these reports.

Topic Measure	QDC Submission Attempts			Total QDCs Reported on Eligible Cases	Denominator Mismatch ^a																Resubmitted QDCs ^f		Unattributed (No NPI) ^g	
	Total QDCs Reported ^d	Total Valid QDCs Reported ^b	% Valid		Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC							
					#	%	#	%	#	%	#	%	#	%	#	%	#	%						
Endoscopy and Polyp Surveillance																								
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	25,486	22,499	88.28%	22,499	0	0.00%	0	0.00%	1,065	4.18%	861	3.38%	991	3.89%	47	0.18%	40	0.16%	0	0.00%	0	0.00%		
Falls																								
#154 Falls: Risk Assessment	310,997	241,846	77.76%	276,711	24,489	7.87%	0	0.00%	31,461	10.12%	0	0.00%	0	0.00%	2,825	0.91%	0	0.00%	0	0.00%	0	0.00%		
#155 Falls: Plan of Care	56,602	32,083	56.68%	32,084	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1,864	3.29%	0	0.00%	0	0.00%	0	0.00%		
Glaucoma																								
#12 Optic Nerve Evaluation	881,798	698,875	79.26%	699,493	1	0.00%	0	0.00%	7,501	0.85%	168,914	19.16%	4,549	0.52%	922	0.10%	4,505	0.51%	2	0.00%	0	0.00%		
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	195,353	163,237	83.56%	174,537	0	0.00%	0	0.00%	1,821	0.93%	18,167	9.30%	500	0.26%	276	0.14%	409	0.21%	0	0.00%	0	0.00%		
Hemodialysis Vascular Access Decision																								
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	2,519	2,306	91.54%	2,306	3	0.12%	0	0.00%	88	3.49%	96	3.81%	14	0.56%	14	0.56%	1	0.04%	0	0.00%	0	0.00%		
Hepatitis C (HCV)																								
#84 Initial Hepatitis C RNA Testing	2,286	2,139	93.57%	2,180	0	0.00%	0	0.00%	31	1.36%	65	2.84%	6	0.26%	4	0.17%	0	0.00%	0	0.00%	0	0.00%		
#85 Genotype Testing Prior to Therapy	2,334	2,161	92.59%	2,217	0	0.00%	0	0.00%	35	1.50%	64	2.74%	8	0.34%	7	0.30%	4	0.17%	0	0.00%	0	0.00%		
#86 Consideration for Antiviral Therapy	1,121	1,014	90.45%	1,014	0	0.00%	0	0.00%	8	0.71%	97	8.65%	0	0.00%	2	0.18%	0	0.00%	0	0.00%	0	0.00%		
#87 RNA Testing at Week 12 of Therapy	1,119	1,029	91.96%	1,043	0	0.00%	0	0.00%	19	1.70%	53	4.74%	2	0.18%	2	0.18%	1	0.09%	0	0.00%	0	0.00%		
#89 Counseling Patients Regarding Use of Alcohol	1,802	1,503	83.41%	1,503	0	0.00%	0	0.00%	20	1.11%	264	14.65%	8	0.44%	6	0.33%	5	0.28%	0	0.00%	0	0.00%		
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	307	195	63.52%	202	0	0.00%	0	0.00%	3	0.98%	14	4.56%	68	22.15%	4	1.30%	16	5.21%	0	0.00%	0	0.00%		
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1,118	890	79.61%	891	0	0.00%	0	0.00%	9	0.81%	211	18.87%	7	0.63%	0	0.00%	2	0.18%	0	0.00%	0	0.00%		
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	1,135	908	80.00%	908	0	0.00%	0	0.00%	9	0.79%	214	18.85%	4	0.35%	0	0.00%	2	0.18%	0	0.00%	0	0.00%		
HIT																								
#124 HIT - Adoption/Use of EHRs	8,291,826	7,903,730	95.32%	7,903,730	0	0.00%	0	0.00%	352,655	4.25%	0	0.00%	0	0.00%	35,413	0.43%	0	0.00%	29	0.00%	12	0.00%		
Imaging																								
#195 Stenosis Measurement in Carotid Imaging Studies	320,657	298,189	92.99%	299,171	0	0.00%	0	0.00%	20,056	6.25%	0	0.00%	0	0.00%	1,430	0.45%	0	0.00%	0	0.00%	0	0.00%		
Imaging-Stroke																								
#10 CT or MRI Reports	302,712	256,574	84.76%	276,514	1	0.00%	0	0.00%	8,256	2.73%	14,393	4.75%	2,144	0.71%	1,261	0.42%	562	0.19%	0	0.00%	0	0.00%		
Influenza																								
#110 Vaccination for Patients >= 50 Years Old	490,766	472,180	96.21%	472,180	8,238	1.68%	0	0.00%	16,585	3.38%	0	0.00%	0	0.00%	1,998	0.41%	0	0.00%	3	0.00%	0	0.00%		
Ischemic Vascular Disease																								
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	120,096	109,779	91.41%	112,935	0	0.00%	0	0.00%	1,070	0.89%	5,658	4.71%	135	0.11%	261	0.22%	165	0.14%	0	0.00%	0	0.00%		
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	128,565	120,095	93.41%	120,095	1	0.00%	0	0.00%	1,178	0.92%	6,635	5.16%	328	0.26%	260	0.20%	478	0.37%	0	0.00%	0	0.00%		
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	75,822	71,622	94.46%	71,622	1	0.00%	0	0.00%	572	0.75%	3,299	4.35%	63	0.08%	228	0.30%	144	0.19%	0	0.00%	0	0.00%		
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	116,509	108,956	93.52%	108,956	0	0.00%	0	0.00%	1,138	0.98%	5,594	4.80%	384	0.33%	364	0.31%	239	0.21%	0	0.00%	0	0.00%		
Leukemia (CLL)																								
#70 Baseline Flow Cytometry	13,387	12,657	94.55%	12,657	0	0.00%	0	0.00%	74	0.55%	622	4.65%	7	0.05%	24	0.18%	9	0.07%	0	0.00%	0	0.00%		
Macular Degeneration																								
#14 Dilated Macular Examination	834,423	803,629	96.31%	804,079	984	0.12%	0	0.00%	8,739	1.05%	18,443	2.21%	1,798	0.22%	1,193	0.14%	486	0.06%	78	0.01%	0	0.00%		
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	497,300	480,232	96.57%	482,919	463	0.09%	0	0.00%	4,660	0.94%	8,091	1.63%	774	0.16%	731	0.15%	244	0.05%	69	0.01%	0	0.00%		
Myelodysplastic Syndrome (MDS) and Acute Leukemias																								
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	14,068	13,094	93.08%	13,094	0	0.00%	0	0.00%	130	0.92%	802	5.70%	15	0.11%	26	0.18%	9	0.06%	0	0.00%	0	0.00%		
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	9,598	8,633	89.95%	9,064	0	0.00%	0	0.00%	72	0.75%	438	4.56%	10	0.10%	12	0.13%	7	0.07%	0	0.00%	0	0.00%		

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Note: Individuals participating in GPRO are excluded from these reports.

Topic Measure	QDC Submission Attempts			Total QDCs Reported on Eligible Cases	Denominator Mismatch ^a																Resubmitted QDCs ^f	Unattributed (No NPI) ^g	
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid		Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC		#	%		#	%
					#	%	#	%	#	%	#	%	#	%	#	%	#	%					
Medication Management																							
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	15,655	2,136	13.64%	3,818	1,206	7.70%	0	0.00%	3,113	19.89%	0	0.00%	0	0.00%	204	1.30%	0	0.00%	0	0.00%	0	0.00%	
#130 Documentation of Current Medications	2,878,660	2,729,495	94.82%	2,729,495	11	0.00%	0	0.00%	134,187	4.66%	0	0.00%	0	0.00%	14,966	0.52%	0	0.00%	12	0.00%	4	0.00%	
Mental Health																							
#134 Screening for Clinical Depression	17,026	11,040	64.84%	11,040	0	0.00%	0	0.00%	5,456	32.05%	0	0.00%	0	0.00%	530	3.11%	0	0.00%	0	0.00%	0	0.00%	
Myeloma																							
#69 Treatment with Bisphosphonates	10,318	9,836	95.33%	9,836	0	0.00%	0	0.00%	83	0.80%	343	3.32%	19	0.18%	26	0.25%	12	0.12%	0	0.00%	0	0.00%	
Myocardial Infarction																							
#28 Aspirin at Arrival	44,099	38,252	86.74%	38,261	0	0.00%	0	0.00%	1,340	3.04%	4,139	9.39%	187	0.42%	107	0.24%	48	0.11%	0	0.00%	0	0.00%	
Nuclear Medicine																							
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	107,535	105,062	97.70%	105,291	0	0.00%	0	0.00%	1,866	1.74%	0	0.00%	0	0.00%	378	0.35%	0	0.00%	0	0.00%	0	0.00%	
Obesity																							
#128 Universal Weight Screening and Follow-Up	406,669	386,414	95.02%	386,414	0	0.00%	0	0.00%	18,871	4.64%	0	0.00%	0	0.00%	1,384	0.34%	0	0.00%	0	0.00%	0	0.00%	
Oncology																							
#156 Oncology: Radiation Dose Limits to Normal Tissues	1,659	1,265	76.25%	1,265	0	0.00%	0	0.00%	65	3.92%	215	12.96%	96	5.79%	14	0.84%	6	0.36%	0	0.00%	0	0.00%	
#194 Oncology: Cancer Stage Documented	49,925	46,449	93.04%	46,479	0	0.00%	0	0.00%	327	0.65%	2,829	5.67%	120	0.24%	140	0.28%	89	0.18%	0	0.00%	0	0.00%	
Osteoporosis																							
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	8,787	3,638	41.40%	3,638	78	0.89%	0	0.00%	170	1.93%	2,718	30.93%	1,222	13.91%	41	0.47%	2,561	29.15%	0	0.00%	0	0.00%	
#39 Screening or Therapy for Women Aged 65 Years and Older	302,721	278,411	91.97%	278,411	7,169	2.37%	9,479	3.13%	20,974	6.93%	0	0.00%	0	0.00%	3,332	1.10%	0	0.00%	4	0.00%	0	0.00%	
#40 Management Following Fracture	74,251	2,069	2.79%	2,069	672	0.91%	0	0.00%	83	0.11%	67,014	90.25%	4,081	5.50%	70	0.09%	4,502	6.06%	0	0.00%	0	0.00%	
#41 Pharmacologic Therapy	59,568	45,538	76.45%	45,538	519	0.87%	0	0.00%	962	1.61%	11,232	18.86%	1,473	2.47%	171	0.29%	685	1.15%	0	0.00%	0	0.00%	
Otitis																							
#91 AOE: Topical Therapy	3,415	3,001	87.88%	3,001	0	0.00%	0	0.00%	32	0.94%	345	10.10%	31	0.91%	5	0.15%	14	0.41%	0	0.00%	0	0.00%	
#92 AOE: Pain Assessment	2,825	2,451	86.76%	2,451	0	0.00%	0	0.00%	40	1.42%	298	10.55%	30	1.06%	5	0.18%	11	0.39%	0	0.00%	0	0.00%	
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	2,244	2,160	96.26%	2,165	0	0.00%	0	0.00%	25	1.11%	50	2.23%	1	0.04%	2	0.09%	2	0.09%	0	0.00%	0	0.00%	
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	219	0	0.00%	0	219	100.00%	0	0.00%	0	0.00%	0	0.00%	219	100.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	
Pain Management																							
#131 Assessment Prior to Initiation of Patient Treatment	292,824	229,500	78.37%	229,500	0	0.00%	0	0.00%	53,362	18.22%	0	0.00%	0	0.00%	9,962	3.40%	0	0.00%	0	0.00%	0	0.00%	
Perioperative																							
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	2,596,053	186,259	7.17%	186,473	148	0.01%	0	0.00%	2,378,476	91.62%	0	0.00%	0	0.00%	31,101	1.20%	0	0.00%	3	0.00%	0	0.00%	
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	175,357	138,659	79.07%	138,660	17	0.01%	0	0.00%	35,646	20.33%	0	0.00%	0	0.00%	1,051	0.60%	0	0.00%	0	0.00%	0	0.00%	
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	166,677	88,318	52.99%	117,602	12	0.01%	0	0.00%	47,731	28.64%	0	0.00%	0	0.00%	1,344	0.81%	0	0.00%	0	0.00%	0	0.00%	
#23 VTE Prophylaxis	133,556	105,296	78.84%	105,297	17	0.01%	0	0.00%	27,492	20.58%	0	0.00%	0	0.00%	765	0.57%	0	0.00%	2	0.00%	0	0.00%	
#30 Timing of Prophylactic Antibiotics - Administering Physician	2,561,697	2,011,206	78.51%	2,032,305	148	0.01%	0	0.00%	515,808	20.14%	0	0.00%	0	0.00%	13,584	0.53%	0	0.00%	2	0.00%	0	0.00%	
#45 Discontinuation of Prophylactic Antibiotics	149,005	33,966	22.80%	42,997	9	0.01%	0	0.00%	103,561	69.50%	0	0.00%	0	0.00%	2,447	1.64%	0	0.00%	0	0.00%	0	0.00%	
Pharyngitis																							
#66 Appropriate Testing for Children	1,009	1	0.10%	1	1,006	99.70%	0	0.00%	0	0.00%	1	0.10%	993	98.41%	0	0.00%	14	1.39%	0	0.00%	0	0.00%	
Pneumonia																							
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	349,669	328,931	94.07%	328,942	4	0.00%	0	0.00%	9,781	2.80%	8,957	2.56%	969	0.28%	975	0.28%	95	0.03%	0	0.00%	1	0.00%	
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	381,227	363,913	95.46%	363,913	4	0.00%	0	0.00%	10,315	2.71%	5,574	1.46%	331	0.09%	1,052	0.28%	117	0.03%	0	0.00%	0	0.00%	
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	342,817	328,911	95.94%	328,971	2	0.00%	0	0.00%	9,316	2.72%	3,103	0.91%	468	0.14%	906	0.26%	80	0.02%	0	0.00%	1	0.00%	
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	234,804	225,338	95.97%	225,338	2	0.00%	0	0.00%	6,479	2.76%	2,042	0.87%	172	0.07%	731	0.31%	57	0.02%	0	0.00%	0	0.00%	

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Note: Individuals participating in GPRO are excluded from these reports.

